S tenting of intra-or extracranial arteries with severe stenosis is likely to be effective for preventing subsequent ischemic stroke by improving cerebral perfusion and reducing the risk of thromboembolism by removing the plaque and eliminating turbulent flow. However, a recent large clinical trial failed to show a beneficial effect of intracranial stenting on secondary stroke prevention.
stenting has been found to be as high as 10.3%, 12 and in one study, 21% of the patients treated with carotid artery stenting demonstrated poststenting silent embolic cerebral infarction (SECI). 13 These silent ischemic lesions presented on diffusion-weighted imaging (DWI) may serve as a useful surrogate marker of clinical stroke occurring after cerebrovascular procedures. 10 Although the technology that protects against thromboembolic complications has tried to enhance the safety of the stenting procedure, 4, 20 the risks posed by these hazardous complications remain a concern.
The importance of dual antiplatelet pretreatment with aspirin and clopidogrel cannot be overemphasized in neurovascular procedures.
2 However, 1 of every 5 patients and 1 of every 2 patients who receive endovascular treatment demonstrate resistance to aspirin and clopidogrel, respectively. 15, 23, 26 The residual platelet reactivity after antiplatelet therapy changes dynamically after stenting procedures. 16 Therefore, in this study we evaluated the association between the change in residual platelet reactivity after dual antiplatelet treatment, measured by antiplatelet resistance, and the occurrence of SECI after stenting.
Methods

Study Population
Patients admitted to the Asan Medical Center for neurovascular stenting of supra-aortic intra-or extracranial arteries between September 2010 and December 2011 were prospectively included in the analysis. Patients aged more than 20 years old with a symptomatic stenosis causing ischemic stroke or transient ischemic attack (within 2 weeks from symptom onset) were included. All endovascular procedures were scheduled on an elective basis. We excluded patients who were 1) receiving emergency procedures in the hyperacute period (within 24 hours from symptom onset); 2) receiving additional procedure such as coiling; 3) were treated for conditions diagnosed as cerebral dissection or vasculitis; or 4) did not take aspirin and/or clopidogrel in accordance with the protocol detailed below. However, ischemic stroke patients undergoing stent insertion as a scheduled procedure during the acute stage (within 7 days from symptom onset) according to the study protocol, after the administration of antiplatelet agents, were enrolled.
Demographic features and vascular risk factors (hypertension, diabetes, hyperlipidemia, and previous stroke history) were obtained for enrolled patients. Routine laboratory tests, including complete blood cell counts and assessment of fibrinogen and C-reactive protein levels, were performed 1 day before the procedure. DWI and measurements of residual platelet reactivity were performed before and after stenting as detailed below. This study was approved by the institutional review board of Asan Medical Center. Written informed consent was obtained from all study participants or their legal representatives.
Premedication and the Extent of Platelet Inhibition
Aspirin and clopidogrel were administered at least 1 day before stenting. Loading doses of antiplatelet agents were administered (aspirin 500 mg and clopidogrel 300 mg) to patients who were naïve to antiplatelet treatment, except for those with a high possibility of bleeding complications. The usual maintenance dosages of aspirin (100 mg per day) and clopidogrel (75 mg per day) were administered to patients who had previously been taking these antiplatelet agents. The maintenance dosage was administered for more than 1 week prior to the procedure. The extent of platelet inhibition by antiplatelet agents was measured using the VerifyNow aspirin and VerifyNow P2Y12 assays (Accumetrics). Aspirin reaction units (ARUs) were measured twice, within 6 hours before the procedure (baseline) and at 24 hours after the procedure (follow-up). P2Y12 reaction units (PRUs) were measured 3 times: at baseline, immediately after the procedure, and at 24 hours' follow-up. Results were expressed as ARUs, PRUs, and the percentage of platelet inhibition (% PI). An ARU value ≥ 550 8 and a PRU value ≥ 275, 22 which have been shown to predict the clinical events more appropriately in this patient population, were defined as resistance to aspirin and clopidogrel, respectively.
MRI and Stenting Procedures
A baseline DWI study was performed within 1 week before the procedure with a 1.5-T MR system (GE Medical Systems) with a standard neurovascular coil. The study was repeated 24 hours after stent insertion. The locations of newly developed SECIs were analyzed. The extent of atherosclerosis was determined by the number of cerebral arteries with significant steno-occlusions (> 50%) and the degree of stenosis on angiography. All image analysis was performed by a stroke neurologist (J.Y.K.) blinded to all the clinical data.
The endovascular procedure was performed under monitored anesthesia by a well-established neurointerventionist. Most of the procedures were performed via femoral artery approach, although in 3 cases the approach was from the right radial artery. For extracranial artery stenting, distal anti-embolic devices were used in most cases (81.8%, 27 of 33). Stent insertion was performed using the Wingspan (Boston Scientific) stent for intracranial arteries, whereas most of the extracranial arteries were stented with open-cell stents such as Precise (Cordis), Acculink (Abbott Vascular), and Protégé (Covidien). Only 1 patient was treated with a closed-cell stent-a Wallstent (Boston Scientific). During the endovascular procedure, patients received 2000 to 5000 IU of intravenous heparin to attain an activated clotting time of approximately 200 seconds or 2-fold higher than baseline. The total procedure time, total dose of heparin, number of stents inserted, diameter and total length of the stent, maximum pressure during ballooning, and site of stent placement were recorded.
Data Analysis
Demographic variables, conventional risk factors, factors related to the procedures, laboratory results, loading of antiplatelet agents, and atherosclerosis status were compared between patients with and without SECI after neurovascular stenting. A chi-square test and Student ttest were used for numerical and categorical variables, as appropriate. Factors with potential association with SECI (p < 0.20) from the univariate logistic regression analysis were entered into the multivariate model. A 2-tailed p value < 0.05 was considered statistically significant. All statistical analyses were performed with SPSS for Windows software (version 17.0; SPSS).
Results
Sixty-nine patients were included according to the predetermined criteria. All the patients underwent MRI before and after stenting. The mean age of the patients was 63.2 years, and 77% were male. Fifty-three patients (77%) presented with cerebral infarction, whereas the remaining 16 patients (23%) had transient ischemic attacks. In 41 patients (59.4%) SECI was identified as a new lesion on a follow-up DWI (+SECI group). The lesion was located only at the vascular territory of the stented vessel in 21 patients (51.2%), whereas in 8 patients (19.5%) DWI demonstrated a lesion outside the territory of the stented vessel. The remaining 12 patients (29.3%) had lesions both inside and outside the vascular territory of the stented vessel.
Comparison of Patients With and Without SECI After Stenting
There were no differences found in terms of risk factors between the patients in the +SECI group and patients without SECI (-SECI group; Table 1 ). SECI was more frequently observed in female patients. The total procedure time and the total amount of heparin used during the procedure, which reflect the technical difficulty of the stenting, were similar in the 2 groups. However, SECI was more frequently observed after stenting for extracranial atherosclerotic stenosis (ECAS) than after stenting for intracranial atherosclerotic stenosis (ICAS). Of the patients who received stenting for ICAS, 43.2% (16 of 37 patients) demonstrated poststenting SECI, whereas 81.5% (22 of 27 patients) and 60.0% (3 of 5 patients) showed SECI after stenting for ECAS and tandem lesions, respectively. The total length of the stent inserted was significantly longer in the +SECI group (mean 31.1 ± 16.5 mm vs 21.8 ± 9.9 mm, p = 0.01).
Extent of Platelet Inhibition and SECI
The baseline ARU and PRU values before stenting were not statistically different between the +SECI and -SECI groups. None of the patients received medications known to influence ARU or PRU values (proton pump inhibitors or nonsteroidal antiinflammatory drugs). Only 2 patients (2.9%) demonstrated aspirin resistance, and only 9 (13.1%) demonstrated clopidogrel resistance at baseline, and there were no differences found between the 2 groups. Among the 9 patients with clopidogrel resistance, 7 patients received additional cilostazol after consideration of the potential benefit of preventing a thrombotic event. Immediately after stent placement, the PRU value increased by 35.3 ± 66.4 in the +SECI group and by 4.7 ± 73.0 in the -SECI group. However, this difference was not statistically significant (p = 0.08).
One day after stent placement, there was no difference found in terms of the ARU or PRU values between the +SECI and -SECI groups (ARU: 420 ± 49 vs 437 ± 85, p = 0.35; and PRU: 224 ± 70 vs 207 ± 76, p = 0.36). There was also no significant change in the ARU values following neurovascular stenting. However, the PRU significantly increased (36 ± 73) in patients with SECI after stenting, whereas it decreased (-12 ± 59) in patients without SECI (p = 0.007; Fig. 1 ). In addition, the number of patients with clopidogrel resistance also increased after stenting in the +SECI group (from 12.2% to 26.8%), whereas there was no increase in the -SECI group ( Table  2) . The mean PRU value in patients with SECI showed a continuous increase after stenting, whereas in patients without SECI, the PRU value reactively increased immediately after stent insertion, but decreased at the 24 hours' follow-up (Fig. 2) .
Independent Predictors of SECI After Neurovascular Stenting
According to the results of univariate binary logistic regression analysis, sex, the site of stent insertion, total length of the stent, and PRU value change between baseline and 24 hours after the procedure were entered into the multivariate analysis. The results showed that the total length of the stent inserted and the change in the PRU value after stenting were independently associated with the occurrence of SECI after neurovascular stenting after adjustment (Table 3) . However, the site of stenting lost its significant association with SECI occurrence in this model.
Discussion
The aim of this study was to evaluate the association between the change of residual platelet reactivity after dual antiplatelet treatment and the occurrence of SECI after stenting. The occurrence of SECI was found not to be associated with the baseline ARU or PRU values measured prior to stenting. However, patients with increasing PRU values 24 hours after stenting compared with baseline demonstrated a higher probability of SECI. The total length of the stent inserted was also associated with the occurrence of SECI.
In our previous study, we found that SECI after coronary angiography was closely associated with the responsiveness to antiplatelet agents that was measured before the endovascular procedures.
14 In contrast, our present results show that the baseline ARU and PRU values are not associated with SECI after stenting in supra-aortic intra-or extracranial arteries. During coronary angiography, the catheter is primarily located at the aortic arch, where the coronary arteries originate, and the procedure itself is static. In contrast, neurovascular stenting requires more manipulations, such as frequent switching of the instruments and the passage of the wire or stenting de-vices through the arteries with heavy atherosclerosis burdens. SECI after neurovascular stenting was found in our analysis to be associated with the total length of the stent inserted and the continuous increase of PRU after stent insertion. Foreign materials inside the vascular space are known to be thrombogenic. 5, 28 Compared with coronary angiography, where the catheter is removed immediately after the procedure, in neurovascular stenting, the stent is permanently inserted inside the vascular wall, and it may increase the platelet reactivity, even after the procedure is completed. Therefore, the inserted stent can cause poststenting thromboembolic events, and those patients with increasing PRU values may be prone to embolic events until the inserted stent is stabilized.
Periprocedural embolic events following neurovascular stenting can have various etiologies. First, the approach of the wires or the stents to the target site can cause embolic events by dislodging thrombi from the atherosclerotic vessels. 7 Second, during the stent deployment, the plaque may be cracked and dislodged and may migrate to distal cere- bral vessels. 3, 27 Finally, the inserted stent can cause embolism until stabilization. 18 Nearly half of the patients in our present study presented with SECI outside of the vascular territory of the stented vessel, and these lesions can be explained by the dislodgement of atheroma that arose during multiple switching and approaches of wires and stents through the more proximal sites (for example, the aortic arch). Previous studies have demonstrated that the nature of the plaque (surface irregularity and high lipid content) is closely associated with the microembolic signals during the procedure.
3, 27 Our current results also demonstrate that the length of the stent, which represents the atherosclerotic burden of the stented site, is associated with the occurrence of SECI. Therefore, the dislodgement of atheroma from the plaque seems to be one of the most important mechanisms involved in SECI occurrence. However, the longer length of the stent does not only present a higher possibility of atheroma dislodgement, it may also induce a larger extent of endothelial injury and release prothrombotic material from the arterial wall and, therefore, cause thromboembolism. High residual platelet activity may potentiate this process.
In a previous study, SECI was observed in only 9% of patients at 1 hour after stenting, compared with 78% at 48 hours after the procedure. 25 Microembolic signals were also detected after the stent insertion. Our present results demonstrate that the increase in PRU level after stenting is independently predictive of SECI. These findings may highlight the importance of embolisms that occur after stent insertion and removal of the catheter. Though the dislodgement of atheroma during stenting is important, various devices are used to protect against embolic barrage during this period. However, after the catheter is re- moved, protection by such devices is impossible. Therefore, the response to antiplatelet agents is critical during this period. As the baseline residual platelet reactivity did not show a significant difference, our study has limitations stemming from the clinical significance. However, our results may help understanding the various causes of cerebral infarction occurring after neurovascular stenting. Especially, the importance of platelet inhibition after stent insertion can be emphasized by our result. Interestingly, only the increase of PRU level (not ARU level) after stenting was associated with the occurrence of SECI. In previous studies, P2Y12 inhibitor resistance was associated with a high rate of adverse events after neurovascular stenting 11, 21 A high PRU level after coronary intervention was also associated with poor prognosis.
24 P2Y12 receptors are critical to the generation of irreversible aggregation through the thromboxane A 2 -dependent pathway.
1 Therefore, the increase in PRU level may be more important for predicting thromboembolic complication after endovascular treatment. Although the values after stenting did not reach the definition of antiplatelet resistance, as the values represent the reactivity of platelets, continuous increase of residual platelet reactivity is associated with the occurrence of embolic events.
There are some noteworthy limitations to our present study. First, the sample size was small. Second, there was heterogeneity with respect to the location of stent placement, and the nature of plaque in ICAS and ECAS may differ. The small sample size limited subanalysis with stratification for ICAS and ECAS. However, the trend of Serial changes in residual platelet reactivity before, immediately after, and 24 hours after stenting. PRU levels showed a continued increase 24 hours after stent insertion in patients with SECI (blue), whereas in patients without SECI (green), PRU levels decreased following an immediate postprocedural transient increase.
PRU level change according to the occurrence of SECI was similar in both ICAS and ECAS stenting (data not shown). Although, our study represents the result of neurovascular stenting overall, further study comparing the change in residual platelet reactivity after stenting ICAS and ECAS is needed. Third, we could not compare the clinical events because of their low incidence. Although SECIs are associated with reduced cognitive function 17 and are widely used as a surrogate, the pathophysiology and the association with residual platelet reactivity may be different from that of symptomatic embolic infarctions. Fourth, no long-term follow-up data are presented. Because the levels of resistance to antiplatelet agents are associated with restenosis, 19 follow-up data evaluated using ultrasonography at the stented area could have strengthened our results. Fifth, the change of PRU level after 24 hours was not documented. The study was initially designed to measure PRU levels until 24 hours after procedure. However, as our results show that PRU levels demonstrated a continuous increase, further study, with PRU levels obtained over a longer followup period, will be needed.
Conclusions
In conclusion, SECI after neurovascular stenting is associated with longer stent length and continuous increase of PRU levels after stent placement. Deploying a long stent may continuously activate platelets during and after the procedure and increase the poststenting embolic risk. Therefore, caution and close observation is needed for these patients.
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